Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CXADR-like membrane protein (CLMP) is a type I transmembrane protein in the immunoglobulin superfamily that localizes to junctional complexes between endothelial and epithelial cells, where it mediates cell-cell adhesion[2][3][5]. It is essential for normal development of the small intestine, with loss-of-function mutations causing congenital short bowel syndrome, a disorder characterized by severe malabsorption and shortened intestinal length[1][2][5]. CLMP also regulates adipocyte differentiation and has been implicated in obesity development due to its expression in adipose tissue[2][5]. Additional proposed roles include promoting leukocyte migration and suppressing colonic tumor growth[6]. No small molecule drugs or targeted therapeutics are currently known, but the protein is actively investigated as a potential therapeutic target, especially for congenital intestinal disorders and obesity[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CXADR-like membrane protein (CLMP).